Pharming Group NV（PHAR）財務資料PHARPharming Group NV

Evaluating the bottom line, Pharming Group N.V. maintains a gross margin of 86.53%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 3.64%, provide a clear picture of how effectively PHAR converts its operational activities into shareholder value.

In the context of the broader market, PHAR competes directly with industry leaders such as ZVRA and AVTX. With a market capitalization of $755.20M, it holds a leading position in the sector. When comparing efficiency, PHAR's gross margin of 86.53% stands against ZVRA's 95.36% and AVTX's N/A. Such benchmarking helps identify whether Pharming Group N.V. is trading at a premium or discount relative to its financial performance.

Pharming expects total revenues for Q3 2026 to reach approximately $117.6 million, a 21% increase from $97.3 million in Q3 2025, indicating strong demand in the rare disease treatment market.